Oxymetazoline Hydrochloride (Nasal Preparation) interactions

Conditions

Conditions in which Oxymetazoline Hydrochloride (Nasal Preparation) needs care, as documented in this source.

• Cardiovascular Diseases

  Moderate

  Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta-1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, and coronary occlusion have been reported rarely during the use of ophthalmic and nasal sympathomimetic agents, but may be more likely if the corneal epithelium is damaged or if an excessive amount of drug is swallowed during nasal administration. Therapy with topical sympathomimetic agents should be administered cautiously in patients with corneal abrasion, sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders, especially coronary insufficiency, cardiac arrhythmia, or hypertension. The potent ophthalmic formulations (e.g., phenylephrine 2.5% or 10%) that are used for diagnostic and pre-surgical purposes should not be used in such patients. For other preparations, it is important that the recommended dosages of the individual products not be exceeded.

  14 sources

  1. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
  2. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  3. "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories
  4. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  5. "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc (2001):
  6. "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough (2001):
  7. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals (2001):
  8. "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough (2001):

  Show all 14 sourcesShow fewer sources

  9. "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals
  10. "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health (2001):
  11. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc (2001):
  12. "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals
  13. "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc (2001):
  14. "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc (2001):

• Diabetes Mellitus

  Moderate

  Topically applied sympathomimetic agents are systemically absorbed, particularly during prolonged or indiscriminate use. Slight increases in blood glucose concentrations may occur with the use of these drugs. Therapy with topical sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate. It is important that the recommended dosages of the individual products not be exceeded.

  14 sources

  1. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
  2. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  3. "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories
  4. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  5. "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc (2001):
  6. "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough (2001):
  7. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals (2001):
  8. "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough (2001):

  Show all 14 sourcesShow fewer sources

  9. "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals
  10. "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health (2001):
  11. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc (2001):
  12. "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals
  13. "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc (2001):
  14. "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc (2001):

• Prostatic Hyperplasia

  Moderate

  Topically applied sympathomimetic agents are systemically absorbed, with the potential for producing clinically significant systemic effects, particularly during prolonged or indiscriminate use. In patients with prostate enlargement, urinary difficulty may develop or worsen due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with topical sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate. It is important that the recommended dosages of the individual products not be exceeded.

  14 sources

  1. Lansche RK "Systemic reactions to topical epinephrine and phenylephrine." Am J Ophthalmol 61 (1966): 95-8
  2. Ellis PP "Systemic reactions to topical therapy." Int Ophthalmol Clin 11 (1971): 1-11
  3. "Product Information. Tyzine Nasal (tetrahydrozoline nasal)." Kenwood Laboratories
  4. "Product Information. Collyrium Fresh (boric acid ophthalmic)." Wyeth-Ayerst Laboratories
  5. "Product Information. Naphcon (naphazoline ophthalmic)." Alcon Laboratories Inc (2001):
  6. "Product Information. Ocuclear (oxymetazoline ophthalmic)." Schering-Plough (2001):
  7. "Product Information. Neo-Synephrine (phenylephrine ophthalmic)." Sanofi Winthrop Pharmaceuticals (2001):
  8. "Product Information. Afrin (oxymetazoline nasal)." Schering-Plough (2001):

  Show all 14 sourcesShow fewer sources

  9. "Product Information. Otrivin (xylometazoline nasal)." Novartis Pharmaceuticals
  10. "Product Information. Privine (naphazoline nasal)." Novartis Consumer Health (2001):
  11. "Product Information. Neo-Synephrine Nasal (phenylephrine nasal)." Southwood Pharmaceuticals Inc (2001):
  12. "Product Information. Vapor Inhaler (levmetamfetamine nasal)." Procter and Gamble Pharmaceuticals
  13. "Product Information. Benzedrex (propylhexedrine nasal)." Menley and James Laboratories Inc (2001):
  14. "Product Information. Pretz-D (ephedrine nasal)." Parnell Pharmaceuticals Inc (2001):